Latest Regulatory Approvals News

Maritana Minerals (ASX:MRT) has reported a 6.3% rise in gold Mineral Resources to 1.86 million ounces and a striking 148% increase in Ore Reserves to 204,100 ounces for FY2026, driven by maiden Ore Reserves at Crake and Kalpini and updates at Boorara.

Fortescue Ltd delivered a record 201.3 million tonnes of iron ore in FY26, alongside a 3% rise in underlying net profit after tax to US$3.47 billion, despite a significant $750 million impairment charge on its Iron Bridge asset. The miner declared a fully franked final dividend of A$0.46 per share and continues to advance its ambitious decarbonisation and growth agenda.

SkyCity Entertainment Group reported a 22% drop in underlying EBITDA for FY26, impacted by regulatory costs and carded play rollout, while progressing asset sales and preparing for New Zealand's online casino market.

Loyal Metals (ASX:LLM) schedules a key court hearing on 24 August to approve PT Bumi Resources’ A$79 million takeover scheme, with most conditions including shareholder approval and project acquisitions progressing smoothly.

Audalia Resources has raised $450,000 through a placement of 15 million shares at 3 cents each, aiming to push the Medcalf project towards production while maintaining working capital.

Energy Fuels Inc. reported a transformative 2024 with a major acquisition boosting its heavy mineral sands assets, a uranium production ramp-up at key US mines, and commercial rare earth oxide output from its White Mesa Mill.

Energy Fuels’ acquisition of Australian Strategic Materials (ASM) has officially closed following Federal Court approval, triggering suspension of ASM trading and setting the stage for shareholder payments and new listings.

Artrya Limited marked its first full year of US commercial operations with a $25.18 million loss, driven by regulatory clearances, customer contracts, and an $80 million capital raise.

Recce Pharmaceuticals has secured ethics approval to add an active-controlled arm to its pivotal Phase 3 trial of RECCE® 327 Topical Gel for diabetic foot infections in Australia, enabling head-to-head comparison against existing antibiotics.

ReNerve Ltd (ASX:RNV) reported an 80% year-on-year revenue increase in Q4 FY26, backed by expanding product lines and a $5 million funding facility. The company is advancing FDA approvals and growing its global distribution footprint, targeting a rapidly expanding $6.19 billion nerve repair biomaterials market.

Atomo Diagnostics has appointed Dr Cheri Walker as interim CEO, replacing founder John Kelly who steps down after 15 years. The leadership change aligns with the company's shift towards commercial growth in the US and Europe.

ImpediMed has secured FDA 510(k) clearance for its SOZO Digital Health Platform to assess sarcopenia risk, marking it as the only FDA-cleared bioimpedance spectroscopy solution for this clinical application. This clearance enables clinicians to non-invasively monitor muscle loss in cancer and chronic disease patients, potentially improving treatment outcomes.